654055-68-2Relevant academic research and scientific papers
Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo
Lu, Jun,Chong, Curtis R.,Hu, Xiaoyi,Liu, Jun O.
, p. 5645 - 5648 (2006)
The fumagillin family of natural products inhibits angiogenesis through the irreversible inhibition of the type 2 methionine aminopeptidase (MetAP2). Herein is reported a novel fumagillin analogue named fumarranol. It is shown that, like fumagillin, fumarranol selectively inhibits MetAP2 and endothelial cell proliferation. It is also active in a mouse model of angiogenesis in vivo. Unlike TNP-470, fumarranol does not covalently bind to MetAP2. Fumarranol may serve as a lead for a new class of angiogenesis inhibitors.
Design, synthesis and evaluation of a series of novel fumagillin analogues
Fardis, Maria,Pyun, Hyung-Jung,Tario, James,Jin, Haolun,Kim, Choung U.,Ruckman, Judy,Lin, Yun,Green, Louis,Hicke, Brian
, p. 5051 - 5058 (2007/10/03)
A series of fumagillin analogues targeted at understanding tolerability of MetAP2 toward substitution at C4 and C6 were synthesized. Initially, the C6 side chain was maintained as cinnamoyl ester and C4 was modified. It was concluded that replacing the na
